Zobrazeno 1 - 10
of 493
pro vyhledávání: '"epratuzumab"'
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 10, Pp 225-236 (2021)
Nikesh N Shah,1 Lubomir Sokol2 1Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA; 2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorresp
Externí odkaz:
https://doaj.org/article/4c7825745919431bb03dcc5e62b8d1cc
Autor:
John A. Reynolds, Jennifer Prattley, Nophar Geifman, Mark Lunt, Caroline Gordon, Ian N. Bruce, on behalf of the MASTERPLANS Consortium
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune condition for which there are limited licensed therapies. Clinical trial design is challenging in SLE due at least in part to imperfect outcome measures. Im
Externí odkaz:
https://doaj.org/article/7b076ac86d794548ad060875f096af9b
Autor:
Bag-Ozbek A, Hui-Yuen JS
Publikováno v:
Therapeutics and Clinical Risk Management, Vol Volume 17, Pp 39-54 (2021)
Ayse Bag-Ozbek,1 Joyce S Hui-Yuen2– 4 1Division of Rheumatology, Renaissance School of Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA; 2Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, N
Externí odkaz:
https://doaj.org/article/0f39e0e280bd46ca8abcec20e52204ff
Autor:
Lubomir Sokol, Nikesh N. Shah
Publikováno v:
ImmunoTargets and Therapy
Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surfa
Autor:
Joyce S Hui-Yuen, Ayse Bag-Ozbek
Publikováno v:
Therapeutics and Clinical Risk Management
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully
Publikováno v:
Česká Stomatologie a Praktické Zubní Lékařství, Vol 115, Iss 3, Pp 27-33 (2015)
Background: Both new active substances and medical devices are used in dentistry. Especially some diseases of the mucous membrane of the mouth, lip vermillion, salivary glands, and bone of jaws are the major focus on drug development. An acyclic nucl
Externí odkaz:
https://doaj.org/article/8653660e0ad8408faf4694109c09a007
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Seminars in Arthritis and Rheumatism. 48:221-239
Objectives To systematically review, and conduct a meta-analysis of steroid-sparing effect in, phase 3 randomized, placebo-controlled trials of biologic therapies for systemic lupus erythematosus (SLE). Methods Studies were identified by searching Me
Publikováno v:
Follicular Lymphoma ISBN: 9783030262105
Monoclonal antibodies (mAb) are critical pieces in the current management of follicular lymphoma and the vast majority of lymphoid malignancies. While most practitioners are very familiar with the use of these drugs, many are not aware that the traje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fab7ba03aa095843a3febe6e9c75d688
https://doi.org/10.1007/978-3-030-26211-2_10
https://doi.org/10.1007/978-3-030-26211-2_10
Autor:
Meng-Jun, Tao, Ping, Cheng, Lai-Run, Jin, Jun, Zhou, Wei, Shi, Hui, Peng, Liang, Xu, Zhi, Li, Hui, Yuan
Publikováno v:
Pakistan Journal of Medical Sciences
Objective: Previous studies have shown that biologic agents out of the nine medicines might be beneficial for the treatment of SLE. The aim of this study was to evaluate the most effective medication of six biologic agents in treatment of SLE using n